Charcoal, activated
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Charcoal, activated
- Molecular weight
- 12.01
- Structure (SMILES)
These details could not be displayed.
- 5 g charcoal powder
- activated charcoal
- Activated charcoal
- Activated Charcoal
- Activated Charcoal suspension
- ast 120
- Ast 120
- AST-120
- AST-120 (Kremezin®)
- carbo vegetabilis
- Carbo vegetabilis
- carbon
- Carbon
- carbon dioxide insufflation
- Carbon dioxide insufflation
- carbon medicinal
- carbon suspension
- carbon-dioxide insufflation
- Carbon, medicinal
- charcoal
- Charcoal
- charcoal activated
- Charcoal, activated
- medicinal carbon
- Medicinal carbon
And 2 more, listed on the interactive page.
- ChEMBL ID
- CHEMBL2106049
- InChIKey
- OKTJSMMVPCPJKN-UHFFFAOYSA-N
- PubChem compound IDs
- 5462310
- RxNorm IDs (RxCUI)
- 272
- A07BA01
- A07BA51
Sources for recorded values
- First in class
- No
- Orphan designation
- No
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Irritable Bowel Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000555
- Subject identifier
- D043183
- Condition
- Inflammatory Bowel Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003767
- Subject identifier
- D015212
- Condition
- Renal Insufficiency, Chronic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003884
- Subject identifier
- D051436
- Condition
- Pouchitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003921
- Subject identifier
- D019449
- Condition
- Gastroesophageal Reflux
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003948
- Subject identifier
- D005764
- Condition
- Sleep Initiation and Maintenance Disorders
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004698
- Subject identifier
- D007319
- Condition
- Brain Diseases
- Highest recorded phase
- 2
- Condition identifier
- HP:0001298
- Subject identifier
- D001927
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition
- Asthma
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition
- Hypersensitivity
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005271
- Subject identifier
- D006967
- Condition
- Multiple Sclerosis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005301
- Subject identifier
- D009103
- Condition
- Lung Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008903
- Subject identifier
- D008175
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000555
- Condition identifier
- EFO_0003767
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003884
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003921
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003948
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009909
- Highest recorded phase
- 2
- Condition identifier
- HP_0001298
- Highest recorded phase
- 2
- Condition identifier
- HP_0001873
- Condition identifier
- HP_0001873
- Highest recorded phase
- 0
- Condition identifier
- HP_0012393
- Condition identifier
- HP_0012393
- Highest recorded phase
- 0
- Condition identifier
- MONDO_0000328
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002108
- Condition identifier
- MONDO_0002108
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002492
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005011
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005052
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005136
- Highest recorded phase
- 2
And 18 more, listed on the interactive page.
- Event
- acute respiratory distress syndrome
- Reports
- 5
- Reporting signal score
- 14.6469
- Event
- areflexia
- Reports
- 2
- Reporting signal score
- 6.8474
- Event
- beta haemolytic streptococcal infection
- Reports
- 2
- Reporting signal score
- 8.60525
- Event
- bezoar
- Reports
- 3
- Reporting signal score
- 14.2136
- Event
- blood creatine phosphokinase mb
- Reports
- 1
- Reporting signal score
- 6.07038
- Event
- blood osmolarity increased
- Reports
- 2
- Reporting signal score
- 10.9579
- Event
- bradycardia
- Reports
- 15
- Reporting signal score
- 34.2789
- Event
- bundle branch block right
- Reports
- 2
- Reporting signal score
- 5.59492
- Event
- cardiac arrest
- Reports
- 7
- Reporting signal score
- 16.373
- Event
- cardiogenic shock
- Reports
- 8
- Reporting signal score
- 28.1914
- Event
- cardioplegia
- Reports
- 1
- Reporting signal score
- 7.51009
- Event
- coma
- Reports
- 7
- Reporting signal score
- 14.2995
- Event
- coma scale abnormal
- Reports
- 5
- Reporting signal score
- 19.7591
- Event
- compartment syndrome
- Reports
- 5
- Reporting signal score
- 21.2849
- Event
- congestive hepatopathy
- Reports
- 1
- Reporting signal score
- 5.61411
- Event
- depressed level of consciousness
- Reports
- 6
- Reporting signal score
- 11.4135
- Event
- electrocardiogram qrs complex prolonged
- Reports
- 2
- Reporting signal score
- 5.51134
- Event
- hyperkalaemia
- Reports
- 8
- Reporting signal score
- 17.8529
- Event
- hypernatraemia
- Reports
- 2
- Reporting signal score
- 5.73879
- Event
- hypotension
- Reports
- 14
- Reporting signal score
- 18.1267
- Event
- hypothermia
- Reports
- 3
- Reporting signal score
- 7.31786
- Event
- ileus
- Reports
- 5
- Reporting signal score
- 14.0643
- Event
- lactic acidosis
- Reports
- 9
- Reporting signal score
- 22.2016
- Event
- left ventricular dysfunction
- Reports
- 4
- Reporting signal score
- 12.5731
- Event
- metabolic acidosis
- Reports
- 7
- Reporting signal score
- 16.5591
And 15 more, listed on the interactive page.
- NCT00321412
- NCT00500682
- NCT00501046
- NCT04311645
- NCT00558038
- NCT00867698
- NCT00583076
- NCT00583531
- NCT00583128
- NCT00587275
- NCT01236105
- NCT01257191
- NCT01389752
- NCT01766843
- NCT01856621
- NCT02237508
- NCT02359292
- NCT02631941
- NCT03073057
- NCT01863888
- NCT06141473
- NCT02123407
- NCT05229874
- NCT02512302
- NCT02691325
And 3 more, listed on the interactive page.
- Hydrogen bond acceptors
- 0
- Hydrogen bond donors
- 0
- Polar surface area
- 0
- Calculated partition coefficient (ALogP)
- 0.08
- Calculated partition coefficient (XLogP)
- 0.6
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 0
- Heavy atoms
- 1
- Molecular formula
- C
- Monoisotopic mass
- 12
- Natural product
- No
Related records
Trials (86)
- 11C- and 18F-Choline PET/MR Imaging for Prostate Cancer
- 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects
- A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers
- A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure
- A Pilot Feasibility Study of Activated Charcoal in Healthy Volunteers
- A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)
- A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)
- A Study on The Effect of Multiple Doses of Activated Charcoal on The Pharmacokinetics of a Single Dose of RO4995819
- A Study to Assess the Absorption, Metabolism and Excretion of [14C]-ANG-3777
- A Study to Compare the Effects of Different Sized Particles on Cells in the Nose
- A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects
- A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants
- Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler
- Activated CHARcoal in Poisoned Patient - Pilot Trial
- Activated Charcoal Use in Chronic Kidney Disease Patients
- Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants
- An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
- Application of Preoperative Axillary Lymph Node Marking With Nano-Carbon in Breast Cancer Patients Before Neoadjuvant Chemotherapy
- Application of Targeted Axillary Lymph Node Resection in Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: an Open-label, Multicenter Study
In development for (16)
- Allergic disease Phase 1
- Asthma Phase 1
- Brain disorder Phase 2
- Chronic kidney disease Phase 3
- Chronic obstructive pulmonary disease Phase 1
- Gastric cancer Phase 3
- Gastroesophageal reflux disease Phase 2
- Inflammatory bowel disease Phase 3
- Insomnia Phase 1
- Irritable bowel syndrome Phase 2
- Lung cancer Phase 2
- Major depressive disorder Phase 1
- Multiple sclerosis Phase 3
- Parkinson disease Phase 1
- Pouchitis Phase 2
- Type 2 diabetes mellitus Phase 1